Abstract
Despite several decades of research, the characteristics distinguishing atypical depression from other depressive subtypes remain ambiguous. Multiple lines of evidence support the designation of atypical depression as a scientifically and clinically relevant subtype, including differences in hormonal responses, brain laterality, psychological profile and psychiatric co-morbidity and differential treatment response. The evolution of the diagnostic criteria for atypical depression has led to the designation of mood reactivity as the cardinal feature, and the research supporting this conclusion is reviewed.
This paper also reviews the evidence for the drug treatment of atypical depression, with a particular focus on research related to the superior efficacy of monoamine oxidase inhibitors (MAOIs) compared with tri cyclic anti-depressants (TCAs). Data relevant to the efficacy of newer antidepressants, including selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline (norepinephrine) reuptake inhibitors, transdermal selegiline and other new agents for atypical depression, are discussed.
In summary, the diagnostic reliability and validity of atypical depression still remain elusive and open to further evolution. Currently available findings suggest that atypical depression has preferential response to MAOIs over TCAs. More data are required to determine the efficacy of newer agents relative to MAOIs and TCAs, although limited studies have shown a noninferior efficacy and better tolerability of newer agents such as SSRIs compared with those of MAOIs and TCAs. Finally, future directions for research include further refinement of the diagnostic criteria for atypical depression, and clarification of the role of newer antidepressants in the treatment of this subtype with evidence from randomized, controlled trials.
Similar content being viewed by others
References
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association, 2000
Parker G, Roy K, Mitchell P, et al. Atypical depression: a reappraisal. Am J Psychiatry 2002 Sep; 159(9): 1470–9
Benazzi F. Testing DSM-IV definition of atypical depression. Ann Clin Psychiatry 2003 Mar; 15(1): 9–16
Horwath E, Johnson J, Weissman MM, et al. The validity of major depression with atypical features based on a community study. J Affect Disord 1992 Oct; 26(2): 117–25
Novick JS, Stewart JW, Wisniewski SR, et al. Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. J Clin Psychiatry 2005 Aug; 66(8): 1002–11
Angst J, Gamma A, Sellaro R, et al. Toward validation of atypical depression in the community: results of the Zurich cohort study. J Affect Disord 2002 Nov; 72(2): 125–38
Stewart JW, McGrath PJ, Quitkin FM. Do age of onset and course of illness predict different treatment outcome among DSM IV depressive disorders with atypical features? Neuropsychopharmacology 2002 Feb; 26(2): 237–45
Kendler KS, Eaves LJ, Walters EE, et al. The identification and validation of distinct depressive syndromes in a population-based sample of female twins. Arch Gen Psychiatry 1996 May; 53(5): 391–9
Zisook S, Shuchter SR, Gallagher T, et al. Atypical depression in an outpatient psychiatric population. Depression 1993; 1: 268–74
Thase ME. Recognition and diagnosis of atypical depression. J Clin Psychiatry 2007; 68 Suppl. 8: 11–6
Alpert JE, Uebelacker LA, McLean NE, et al. Social phobia, avoidant personality disorder and atypical depression: cooccurrence and clinical implications. Psychol Med 1997 May; 27(3): 627–33
Marcus SM, Young EA, Kerber KB, et al. Gender differences in depression: findings from the STAR*D study. J Affect Disord 2005 Aug; 87(2–3): 141–50
Levitan RD, Lesage A, Parikh SV, et al. Reversed neurovegetative symptoms of depression: a community study of Ontario. Am J Psychiatry 1997 Jul; 154(7): 934–40
Asnis GM, McGinn LK, Sanderson WC. Atypical depression: clinical aspects and noradrenergic function. Am J Psychiatry 1995 Jan; 152(1): 31–6
Quitkin FM, Stewart JW, McGrath PJ, et al. Columbia atypical depression: a subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry Suppl 1993; 163 Suppl. 21: 30–4
McGinn LK, Asnis GM, Rubinson E. Biological and clinical validation of atypical depression. Psychiatry Res 1996 Mar 29; 60(2–3): 191–8
Geracioti Jr TD, Loosen PT, Orth DN. Low cerebrospinal fluid corticotropin-releasing hormone concentrations in eucortisolemic depression. Biol Psychiatry 1997 Aug 1; 42(3): 165–74
West ED, Dally PJ. Effect of iproniazid in depressive syndromes. Br Med J 1959; 1: 1491–4
Quitkin FM, McGrath PJ, Stewart JW, et al. Phenelzine and imipramine in mood reactive depressives: further delineation of the syndrome of atypical depression. Arch Gen Psychiatry 1989 Sep; 46(9): 787–93
Nierenberg AA, Alpert JE, Pava J, et al. Course and treatment of atypical depression. J Clin Psychiatry 1998; 59 Suppl. 18: 5–9
Bruder GE, Stewart JW, McGrath PJ, et al. Atypical depression: enhanced right hemispheric dominance for perceiving emotional chimeric faces. J Abnorm Psychology 2002 Aug; 111(3): 446–54
Fotiou F, Fountoulakis KN, Iacovides A, et al. Patternreversed visual evoked potentials in subtypes of major depression. Psychiatry Res 2003 Jun 15; 118(3): 259–71
Fountoulakis KN, Iacovides A, Gerasimou G, et al. The relationship of regional cerebral blood flow with subtypes of major depression. Prog Neuropsychopharmacology Biol Psychiatry 2004 May; 28(3): 537–46
Parker GB. Atypical depression: a valid subtype? J Clin Psychiatry 2007; 68Suppl. 3: 18–22
Sargant W. Some newer drugs in the treatment of depression and their relation to other somatic treatments. Psychsomatics 1960; 1: 14–7
Robinson DS, Nies A, Ravaris CL, et al. The monoamine oxidase inhibitor, phenelzine, in the treatment of depressiveanxiety states: a controlled clinical trial. Arch Gen Psychiatry 1973 Sep; 29(3): 407–13
Quitkin F, Rifkin A, Klein DF. Monoamine oxidase inhibitors: a review of antidepressant effectiveness. Arch Gen Psychiatry 1979 Jul; 36(7): 749–60
Davidson JR, Miller RD, Turnbull CD, et al. Atypical depression. Arch Gen Psychiatry 1982 May; 39(5): 527–34
Quitkin FM, Stewart JW, McGrath PJ, et al. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry 1988 Mar; 145(3): 306–11
Posternak MA, Zimmerman M. Partial validation of the atypical features subtype of major depressive disorder. Arch Gen Psychiatry 2002 Jan; 59(1): 70–6
Sullivan PF, Kessler RC, Kendler KS. Latent class analysis of lifetime depressive symptoms in the National Comorbidity Survey. Am J Psychiatry 1998 Oct; 155(10): 1398–406
Perugi G, Akiskal HS, Lattanzi L, et al. The high prevalence of “soft” bipolar (II) features in atypical depression. Compr Psychiatry 1998 Mar–Apr; 39(2): 63–71
Robertson HA, Lam RW, Stewart JN, et al. Atypical depressive symptoms and clusters in unipolar and bipolar depression. Acta Psychiatr Scand 1996 Dec; 94(6): 421–7
Davidson JR. A history of the concept of atypical depression. J Clin Psychiatry 2007; 68 Suppl. 3: 10–5
Saunders JC, Radinger N, Rochlin D, et al. Treatment of depressed and regressed patients with iproniazid and reserpine. Dis Nerv Syst 1959 Jan; 20(1): 31–9
Delay J, Buisson JF. Psychic action of isoniazid in the treatment of depressive states. J Clin Exp Psychopathol 1958 Apr–Jun; 19(2 Suppl. 1): 51–5
Davidson JR, Giller EL, Zisook S, et al. An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology. Arch Gen Psychiatry 1988 Feb; 45(2): 120–7
McGrath PJ, Stewart JW, Harrison W, et al. A placebocontrolled trial of L-deprenyl in atypical depression. Psychopharmacol Bull 1989; 25(1): 63–7
Liebowitz MR, Quitkin FM, Stewart JW, et al. Phenelzine v imipramine in atypical depression: a preliminary report. Arch Gen Psychiatry 1984 Jul; 41(7): 669–77
Liebowitz MR, Quitkin FM, Stewart JW, et al. Anti-depressant specificity in atypical depression. Arch Gen Psychiatry 1988 Feb; 45(2): 129–37
Quitkin FM, McGrath PJ, Stewart JW, et al. Atypical depression, panic attacks, and response to imipramine and phenelzine: a replication. Arch Gen Psychiatry 1990 Oct; 47(10): 935–41
Quitkin FM, Harrison W, Stewart JW, et al. Response to phenelzine and imipramine in placebo nonresponders with atypical depression: a new application of the crossover design. Arch Gen Psychiatry 1991 Apr; 48(4): 319–23
Pande AC, Birkett M, Fechner-Bates S, et al. Fluoxetine versus phenelzine in atypical depression. Biol Psychiatry 1996 Nov 15; 40(10): 1017–20
McGrath PJ, Stewart JW, Nunes EV, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 1993 Jan; 150(1): 118–23
Parsons B, Quitkin FM, McGrath PJ, et al. Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull 1989; 25(4): 524–34
Stewart JW, Tricamo E, McGrath PJ, et al. Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months’ remission. Am J Psychiatry 1997 Jan; 154(1): 31–6
Jarrett RB, Schaffer M, McIntire D, et al. Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999 May; 56(5): 431–7
Larsen JK, Gjerris A, Holm P, et al. Moclobemide in depression: a randomized, multicentre trial against isocarboxazide and clomipramine emphasizing atypical depression. Acta Psychiatr Scand 1991 Dec; 84(6): 564–70
Larsen JK, Holm P, Mikkelsen PL. Moclobemide and clomipramine in the treatment of depression: a randomized clinical trial. Acta Psychiatr Scand 1984 Sep; 70(3): 254–60
Sogaard J, Lane R, Latimer P, et al. A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. J Psychopharmacol 1999 Dec; 13(4): 406–14
Lonnqvist J, Sihvo S, Syvalahti E, et al. Moclobemide and fluoxetine in atypical depression: a double-blind trial. J Affect Disord 1994 Nov; 32(3): 169–77
McGrath PJ, Stewart JW, Janal MN, et al. A placebocontrolled study of fluoxetine versus imipramine in the acute treatment of atypical depression. Am J Psychiatry 2000 Mar; 157(3): 344–50
Stratta P, Bolino F, Cupillari M, et al. A double-blind parallel study comparing fluoxetine with imipramine in the treatment of atypical depression. Int Clin Psychopharmacol 1991 Winter; 6(3): 193–6
Joyce PR, Mulder RT, Luty SE, et al. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust N Z J Psychiatry 2002 Jun; 36(3): 384–91
Pae CU, Masand PS, Peindl K, et al. An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features. Prim Care Companion J Clin Psychiatry 2008; 10(3): 205–10
Henkel V, Mergl R, Allgaier AK, et al. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res 2006 Jan 30; 141(1): 89–101
Lecrubier Y, Pedarriosse AM, Payan C, et al. Moclobemide versus clomipramine in nonmelancholic, nonpsychotic major depression: a study group. Acta Psychiatr Scand 1995 Oct; 92(4): 260–5
Dierick M, Cattiez P, Franck G, et al. Moclobemide versus clomipramine in the treatment of depression: a double-blind multicentre study in Belgium. Acta Psychiatr Scand Suppl 1990; 360: 50–1
Tiller J, Schweitzer I, Maguire K, et al. A sequential double-blind controlled study of moclobemide and diazepam in patients with atypical depression. J Affect Disord 1989 Mar-Jun; 16(2-3): 181–7
Schweitzer I, Tiller J, Maguire K, et al. Treatment of atypical depression with moclobemide: a sequential double controlled study. Int J Clin Pharmacol Res 1989; 9(2): 111–7
Quitkin FM. Depression with atypical features: diagnostic validity, prevalence, and treatment. Prim Care Companion J Clin Psychiatry 2002 Jun; 4(3): 94–9
Reimherr FW, Wood DR, Byerley B, et al. Characteristics of responders to fluoxetine. Psychopharmacol Bull 1984; 20(1): 70–2
Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9
Goodnick PJ, Extein IL. Bupropion and fluoxetine in depressive subtypes. Ann Clin Psychiatry 1989; 1: 119–22
Roose SP, Miyazaki M, Devanand D, et al. An open trial of venlafaxine for the treatment of late-life atypical depression. Int J Geriatr Psychiatry 2004 Oct; 19(10): 989–94
Rye DB, Dihenia B, Bliwise DL. Reversal of atypical depression, sleepiness, and REM-sleep propensity in narcolepsy with bupropion. Depress Anxiety 1998; 7(2): 92–5
Stewart JW, Deliyannides DA, McGrath PJ. Is duloxetine effective treatment for depression with atypical features? Int Clin Psychopharmacol 2008 Nov; 23(6): 333–6
Hyman Rapaport M. Translating the evidence on atypical depression into clinical practice. J Clin Psychiatry 2007; 68 Suppl. 3: 31–6
Papakostas GI, Nutt DJ, Hallett LA, et al. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry 2006 Dec 15; 60(12): 1350–5
Pae CU, Lim HK, Han C, et al. Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion. Expert Rev Neurother 2007 Oct; 7(10): 1251–63
Liebowitz MR, Karoum F, Quitkin FM, et al. Biochemical effects of L-deprenyl in atypical depressives. Biol Psychiatry 1985 May; 20(5): 558–65
Quitkin FM, Liebowitz MR, Stewart JW, et al. l-Deprenyl in atypical depressives. Arch Gen Psychiatry 1984 Aug; 41(8): 777–81
Patkar AA, Pae CU, Masand PS. Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr 2006 May; 11(5): 363–75
Patkar AA, Pae CU, Zarzar M. Transdermal selegiline. Drugs Today (Barc) 2007 Jun; 43(6): 361–77
Pae CU, Lim HK, Han C, et al. Selegiline transdermal system: current awareness and promise. Prog Neuropsychopharmacol Biol Psychiatry 2007 Aug 15; 31(6): 1153–63
Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallelgroup study in outpatients. Am J Psychiatry 2002 Nov; 159(11): 1869–75
Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003 Feb; 64(2): 208–14
Feiger AD, Rickels K, Rynn MA, et al. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry 2006 Sep; 67(9): 1354–61
Amsterdam JD, Bodkin JA. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallelgroup clinical trial. J Clin Psychopharmacol 2006 Dec; 26(6): 579–86
Docherty JP, Sack DA, Roffman M, et al. A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving. J Psychiatr Pract 2005 Sep; 11(5): 302–14
Davidson JR, Abraham K, Connor KM, et al. Effectiveness of chromium in atypical depression: a placebo-controlled trial. Biol Psychiatry 2003 Feb 1; 53(3): 261–4
Vaishnavi S, Gadde K, Alamy S, et al. Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment. J Clin Pharmacol 2006 Aug; 26(4): 373–8
Thase ME, Fava M, DeBattista C, et al. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr 2006 Feb; 11(2): 93–102
DeBattista C, Doghramji K, Menza MA, et al. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry 2003 Sep; 64(9): 1057–64
McGrath PJ, Stewart JW, Quitkin FM, et al. Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement. J Clin Pharmacol 1994 Oct; 14(5): 347–52
Murck H. Atypical depression and related illnesses: neurobiological principles for their treatment with Hypericum extract [in German]. Wien Med Wochenschr 2002; 152(15–16): 398–403
Leppamaki S, Partonen T, Vakkuri O, et al. Effect of controlled-release melatonin on sleep quality, mood, and quality of life in subjects with seasonal or weatherassociated changes in mood and behaviour. Eur Neuropsychopharmacol 2003 May; 13(3): 137–45
Mahajan T, Crown A, Checkley S, et al. Atypical depression in growth hormone deficient adults, and the beneficial effects of growth hormone treatment on depression and quality of life. Eur J Endocrinol 2004 Sep; 151(3): 325–32
Mercier MA, Stewart JW, Quitkin FM. A pilot sequential study of cognitive therapy and pharmacotherapy of atypical depression. J Clin Psychiatry 1992 May; 53(5): 166–70
Jarrett RB, Kraft D, Schaffer M, et al. Reducing relapse in depressed outpatients with atypical features: a pilot study. Psychother Psychosom 2000 Sep–Oct; 69(5): 232-9
Acknowledgements
This research was supported by a grant from the Medical Research Center, Korea Science and Engineering Foundation, Republic of Korea (R13-2002-005-04001-0).
Dr Pae has received research grants from GlaxoSmithKline Korea, AstraZeneca Korea, Janssen Pharmaceutica Korea, Eli Lilly and Company Korea, Korean Research Foundation, Otsuka Korea, Wyeth Korea, and the Korean Institute of Science and Technology Evaluation and Planning. He has received honoraria and is on the speakers’ bureaus of GlaxoSmithKline Korea, Lundbeck Korea, AstraZeneca Korea, Janssen Pharmaceutica Korea, Eli Lilly and Company Korea, McNeil Consumer and Specialty Inc. and Otsuka Korea.
Dr Marks is a consultant for Bristol-Myers Squibb and is on the speakers’ bureaus of Eli Lilly and Company and Pfizer Inc. He has received research support from Merck and Johnson & Johnson.
Dr Patkar is a consultant for Bristol-Myers Squibb, GlaxoSmithKline and Reckitt Benckiser. He is on the speakers’ bureaus and has received honoraria from Bristol-Myers Squibb, Cephalon, Pfizer Inc. and Reckitt Benckiser. He has received grant support from the National Institutes of Health, AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Janssen Pharmaceutica, Jazz Pharmaceuticals, Lundbeck, McNeil Consumer & Specialty Inc., Organon and Pfizer Inc.
Dr Masand is a consultant for Bristol-Myers Squibb, Eli Lilly and Company, i3 CME, Janssen Pharmaceutica, Organon and Pfizer Inc. He is on the speakers’ bureaus of Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutica, Pfizer Inc. and Eli Lilly and Company.
Dr Tharwani has no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pae, CU., Tharwani, H., Marks, D.M. et al. Atypical Depression. CNS Drugs 23, 1023–1037 (2009). https://doi.org/10.2165/11310990-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11310990-000000000-00000